Outcome according to KRAS-, NRAS- and BRAF-mutation as well as KRAS mutation variants: pooled analysis of five randomized trials in metastatic colorectal cancer by the AIO colorectal cancer study group

Breast Cancer

Recent Developments in Metastatic Breast Cancer

healthbook TIMES Oncology Hematology

Gastrointestinal CancerFurther Publications

Targeting the Tumor in Colorectal Cancer – Where do we Stand with Precision Medicine in 2020

★ 3 Recommended and commented by Alexander Meisel, Faculty Member

healthbook TIMES Oncology Hematology

Corresponding author: Dr Alexander Siebenhüner Senior Consultant in Medical Oncology Cantonal Hospital Schaffhausen Schaffhausen, Switzerland

Gastrointestinal Cancer

The Role of Maintenance Strategies in Metastatic Colorectal Cancer: A Systematic Review and Network Meta-analysis of Randomized Clinical Trials

JAMA Oncol.

Sonbol MB, Mountjoy LJ, Firwana B, Liu AJ, Almader-Douglas D, Mody K, Hubbard J, Borad M, Ahn DH, Murad MH, Bekaii-Saab T

doi: 10.1001/jamaoncol.2019.4489.

Gastrointestinal Cancer

KRAS and BRAF Mutations in Stage II/III Colon Cancer: A Systematic Review and Meta-Analysis

J Natl Cancer Inst

Formica V, Sera F, Cremolini C, Riondino S, Morelli C, Arkenau HT, Roselli M

doi: 10.1093/jnci/djab190

Gastrointestinal Cancer

A polymorphism within the R-spondin 2 gene predicts outcome in metastatic colorectal cancer patients treated with FOLFIRI/bevacizumab: data from FIRE-3 and TRIBE trials

Eur J Cancer.

Berger MD, Ning Y, Stintzing S, Heinemann V, Cao S, Zhang W, Yang D, Miyamoto Y, Suenaga M, Schirripa M, Hanna DL, Soni S, Puccini A, Tokunaga R, Naseem M, Battaglin F, Cremolini C, Falcone A, Loupakis F, Lenz HJ

doi: 10.1016/j.ejca.2020.02.048.

Gastrointestinal Cancer

BRAF and NRAS locus specific variants have different outcomes on survival to colorectal cancer

Clin Cancer Res.

Summers M, Smith CG, Maughan TS, Kaplan R, Escott-Price V, Cheadle JP

doi: 10.1158/

Gastrointestinal Cancer

Association of BRAF Mutations With Survival and Recurrence in Surgically Treated Patients With Metastatic Colorectal Liver Cancer

JAMA Surg.

Margonis GA, Buettner S, Andreatos N, Kim Y, Wagner D, Sasaki K, Beer A, Schwarz C, Løes IM, Smolle M, Kamphues C, He J, Pawlik TM, Kaczirek K, Poultsides G, Lønning PE, Cameron JL, Burkhart RA, Gerger A, Aucejo FN, Kreis ME, Wolfgang CL, Weiss MJ

doi: 10.1001/jamasurg.2018.0996.

Gastrointestinal Cancer

Prognostic association of PTGS2 (COX-2) over-expression according to BRAF mutation status in colorectal cancer: Results from two prospective cohorts and CALGB 89803 (Alliance) trial

Eur J Cancer.

Kosumi K, Hamada T, Zhang S, Liu L, da Silva A, Koh H, Twombly TS, Mima K, Morikawa T, Song M, Nowak JA, Nishihara R, Saltz LB, Niedzwiecki D, Ou FS, Zemla T, Mayer RJ, Baba H, Ng K, Giannakis M, Zhang X, Wu K, Giovannucci EL, Chan AT, Fuchs CS, Meyerhardt JA, Ogino S

doi: 10.1016/j.ejca.2019.01.022.

Gastrointestinal Cancer

Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal Cancer: The Canadian Cancer Trials Group CO.26 Study

JAMA Oncol.

Chen EX, Jonker DJ, Loree JM, Kennecke HF, Berry SR, Couture F, Ahmad CE, Goffin JR, Kavan P, Harb M, Colwell B, Samimi S, Samson B, Abbas T, Aucoin N, Aubin F, Koski SL, Wei AC, Magoski NM, Tu D, O'Callaghan CJ

doi: 10.1001/jamaoncol.2020.0910.

Related content

Recent Developments in Metastatic Breast Cancer

Targeting the Tumor in Colorectal Cancer – Where do we Stand with Precision Medicine in 2020

The Role of Maintenance Strategies in Metastatic Colorectal Cancer: A Systematic Review and Network Meta-analysis of Randomized Clinical Trials

KRAS and BRAF Mutations in Stage II/III Colon Cancer: A Systematic Review and Meta-Analysis

A polymorphism within the R-spondin 2 gene predicts outcome in metastatic colorectal cancer patients treated with FOLFIRI/bevacizumab: data from FIRE-3 and TRIBE trials

BRAF and NRAS locus specific variants have different outcomes on survival to colorectal cancer

Association of BRAF Mutations With Survival and Recurrence in Surgically Treated Patients With Metastatic Colorectal Liver Cancer

Prognostic association of PTGS2 (COX-2) over-expression according to BRAF mutation status in colorectal cancer: Results from two prospective cohorts and CALGB 89803 (Alliance) trial

Effect of Combined Immune Checkpoint Inhibition vs Best Supportive Care Alone in Patients With Advanced Colorectal Cancer: The Canadian Cancer Trials Group CO.26 Study